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Abstract
Gemcitabine and cisplatin chemotherapy (GC regimen) represents a standard treatment
for advanced urothelial carcinoma. We performed an open-label, single-arm,
non-randomised, phase 2 trial evaluating the addition of sunitinib to standard GC
chemotherapy (SGC regimen). Overall, 63 treatment-naı¨ve participants were recruited
and received up to six 21-d cycles of cisplatin 70 mg/m2 (intravenously [IV], day 1) and
gemcitabine 1000 mg/m2 (IV, days 1 and 8) combined with sunitinib 37.5 mg (orally,
days 2–15). Following review of toxicity after the ﬁrst six patients, the sunitinib dose
was reduced to 25 mg for all patients. Overall response rate was 64%, with response
noted in 37 of 58 patients. At 6 mo, 30 of 58 assessable patients (52%; 90% conﬁdence
interval [CI], 40–63%) were progression free. Median overall survival was 12mo (95% CI,
9–15) andwas heavily inﬂuenced by Bajorin prognostic group. Grade 3–4 toxicitieswere
predominantly haematologic and limited the deliverability of the triple SGC regimen.
The trial did not meet its prespeciﬁed primary end point of >60% patients progression
free at 6 mo. Cumulative myelosuppression led to treatment delays of gemcitabine and
cisplatin and dose reduction and/or withdrawal of sunitinib in the majority of cases. The
triple-drug combination was not well tolerated. Phase 3 evaluation of the triple SGC
regimen in advanced transitional cell carcinoma is not recommended.
Patient summary: The addition of sunitinib to standard cisplatin and gemcitabine
chemotherapy was poorly tolerated and did not improve outcomes in advanced urothe-
lial carcinoma. Treatment delivery was limited by myelotoxicity.
# 2014 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).* Corresponding author. Cardiff University,Wales Cancer Trials Unit, 6th Floor, NeuaddMeirionnydd,
Heath Park, Cardiff, CF144YS, UK. Tel. +44 2920687470.
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0302-2838/# 2014 European Association of Urology. Published by Elsevier B
license (http://creativecommons.org/licenses/by/4.0/)..V. This is an open access article under the CC BY
Table 1 – Overall outcome
Outcome Results
Primary end point
6-mo PFS (n = 58*), % (90% CI) 52 (40–63)
Secondary end points
Overall response rate (n = 58), n (%) 37 (64)
CR 12 (21)
PR 25 (43)
SD 8 (14)
Disease control, CR + PR + SD 45 (78)
Time-to-event PFS (n = 63), mo, median (95% CI) 8 (6–11)
Time-to-event OS (n = 63), mo, median (95% CI) 12 (9–15)
Time-to-event OS by Bajorin prognostic group, mo, median (95% CI)
Good prognosis (n = 25) 21 (10–NR)
Intermediate prognosis (n = 36) 10 (8–14)
Poor prognosis (n = 2) 4 (4–NR)
* Five of 63 patients withdrew prior to response assessment.
CI = confidence interval; CR = complete response; NR = not reached;
OS = overall survival; PFS = progression-free survival; PR = partial response;
SD = stable disease.
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carcinoma is poor, and in the United Kingdom, approxi-
mately 5000 patients die each year from this disease
[1]. Combination gemcitabine and cisplatin chemotherapy
(GC regimen) represents a current standard of care in this
disease setting, with randomised controlled trial evidence
demonstrating progression-free survival (PFS) of 7 mo and
overall survival (OS) of 14 mo in the first-line setting [2].
Novel targeted agents have led to significant improve-
ments in outcome for patients with a wide variety of
malignancies, but there have been few studies in advanced
urothelial cancer. Sunitinib, an oral multitargeted-receptor
tyrosine kinase inhibitor, has potent antiangiogenic and
antitumour activity. Microvessel density (a measure of
tumour angiogenesis) and high serum vascular endothelial
growth factor (VEGF) levels appear to be associated with a
poorer outcome in urothelial carcinoma and, in particular,
may be associated with higher disease stage, higher grade,
vascular invasion, and poorer disease-free survival
[3,4]. Preclinical and early phase clinical studies confirmed
activity of sunitinib in urothelial cancer and showed that it
could be combined with GC cytotoxic chemotherapy [5–7].
In this open-label, single-arm, non-randomised, phase
2 trial, we evaluated the addition of sunitinib to standardGC
chemotherapy (SGC regimen; detailed inclusion criteria,
efficacy assessments, and statistical considerations are
shown in the supplementary data). Eligibility criteria
included patients with World Health Organisation perfor-
mance status of 0–2 and advanced, histologically confirmed
urothelial (transitional cell) carcinomawhowere fit enough
to receive cisplatin-containing chemotherapy. All patients
received up to six 21-d cycles of GC chemotherapy (cisplatin
70 mg/m2 intravenously [IV] on day 1, gemcitabine
1000 mg/m2 IV on days 1 and 8) in combination with
sunitinib 37.5 orally each day on days 2–15. Following
review of haematologic toxicity after enrolment of the first
six patients, sunitinib dose was reduced to 25 mg orally
each day on days 2–15 for all patients.
The primary end point of the study was PFS at 6 mo. The
sample size of 63 was based on Fleming’s one-stage design
using a significance level (one-sided) of 10% and 90% power.
The expected PFS at 6 mo following treatment with
standard GC chemotherapy was approximately 65%
[2]. PFS at 6 mo of <60% was deemed to be insufficiently
large enough to warrant further investigation. Secondary
end points included time-to-event analysis of PFS and OS,
safety, tolerability, and objective overall response rate
(ORR).
Between 31 July 2009 and 1 February 2013, 63 patients
were recruited from 11 institutions in the United Kingdom
(patient characteristics and CONSORT diagram are shown in
Fig. 1; supplementary data). Overall, 58 patients were
included in the analysis of PFS and ORR. All 63 patients were
included in the secondary analyses.
Treatment-related outcomes are summarised in Table 1
and Figure 1. Patients received a median of six cycles of
treatment (interquartile range: 3–6). Moreover, 21% (12 of
58 patients) achieved complete radiologic response, 43%
(25 of 58) achieved partial response, and 14% (8 of 58)achieved stable disease, for an ORR of 64% and a disease
control rate of 78%.
At 6 mo, 52% (30 of 58 patients) remained progression
free (90% confidence interval [CI], 40–63%). For the time-to
event-analysis, the median PFS for all patients was 8 mo
(95% CI, 6–11). A total of 39 patients (62%) died of
progressive disease. Median OS was 12 mo (95% CI, 9–15).
Table 2 summarises all reported, treatment-related,
Common Terminology Criteria for Adverse Events grade 3–
4 toxicities occurring in >5% of patients during treatment.
Reported toxicities were predominantly haematologic.
Prolonged myelosuppression was common. Despite a
reduction in the starting dose of sunitinib from 37.5 mg to
25 mg, the majority of patients required further sunitinib
dose reduction or withdrawal for a variety of reasons
including intolerance of treatment (n = 18), clinician choice
(n = 11), disease progression (n = 5), patient choice (n = 2),
poor performance status (n = 1), and bowel obstruction
(n = 1). Nonhaematologic toxicities were infrequently
reported, with grade 3–4 fatigue occurring in five patients
(8%) and gastrointestinal toxicity (nausea, vomiting, and
diarrhoea, combined) in sevenpatients (11%). By cycle 6, only
33% of patients remained on full dose sunitinib; cisplatin and
gemcitabine doses were well preserved, but dose delay was
common.Relativedose intensity fellwith successive cyclesof
treatment (Figure 2 and Table 2, supplementary data).
There was no evidence that treatment outcomes were
improved following the addition of sunitinib. The triple SGC
regimen was associated with high levels of haematologic
toxicity and dose delay. Response rate was in keeping with
that expected for GC alone, and no improvement was found
in PFS or OS following the addition of sunitinib. OS was
heavily influenced by Bajorin risk group [8]. No evidence
showed that sunitinib improved outcome in any subgroup,
although the number of patients with poor-prognosis
disease was small (Table 1, Fig. 1C).
The combination of sunitinib with standard cytotoxic
chemotherapy appears to prolong the duration of myelo-
suppression seen with standard cytotoxic chemotherapy.
Although myelotoxicity is seen with single-agent sunitinib,
[(Fig._1)TD$FIG]
Fig. 1 – (A) Progression-free survival, (B) overall survival (OS), and (C) OS by Bajorin prognostic group.
[(Fig._2)TD$FIG]
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occurring in <10% of patients. The toxicities and outcomes
seen in our study are in keeping with updated results from
the original phase 1 SGC study in lung cancer and two
smaller contemporaneous studies that sought to combine
standard cytotoxic chemotherapy with sunitinib in patients
with urothelial carcinoma [9,10]. The synergistic myelo-
suppressive effects of sunitinib may relate to inhibition ofTable 2 – Treatment-related toxicity (grade I3) occurring in I5%
of patients in one cycle or more of treatment
Toxicity Worst grade reported, n (%)
3 4 3 or 4
Overall worst grade per
patient (any toxicity)
18 (28.6) 36 (57.1) 54 (85.7)
Anaemia 15 (23.8) 1 (1.6) 16 (25.4)
Leukopenia 32 (50.8) 8 (12.7) 40 (63.5)
Neutropenia 16 (25.4) 31 (49.2) 47 (74.6)
Thrombocytopenia 21 (33.3) 12 (19.0) 33 (52.3)
Neutropenic fever or sepsis 4 (6.3) 3 (4.8) 7 (11.1)
Combined GI toxicity (nausea,
vomiting, or diarrhoea)
7 (11.1) 0 (0.0) 7 (11.1)
Fatigue 5 (7.9) 0 (0.0) 5 (7.9)
GI = gastrointestinal.receptor tyrosine kinases other thanVEGF, and itmaybe that
these ‘‘off-target’’ effects of sunitinib are important for bone
marrow recovery following standard cytotoxic chemothera-
py. Given the potentially important role of angiogenesis in
the development and progression of advanced urothelial
cancer, alternative strategies for targeting the VEGF pathwayFig. 2 – Relative dose intensity (actual dose intensity divided by expected
dose intensity) by cycle and treatment.
RDI = relative dose intensity.
E U RO P E AN URO LOGY 6 7 ( 2 0 1 5 ) 5 9 9 – 6 0 2602may prove more fruitful. A large phase 3 trial is currently
under way to evaluate standard GC chemotherapy with
or without bevacizumab in the treatment of advanced
transitional cell carcinoma (ClinicalTrials.gov identifier
NCT00942331).
In conclusion, the addition of sunitinib to standard-dose
GC chemotherapy was not well tolerated, and no evidence
showed improved outcomes for patients with advanced
urothelial carcinoma. Treatment was limited by cumulative
myelotoxicity. These results are in keeping with clinical
trials using sunitinib and cytotoxic chemotherapy combi-
nations in other solid tumours. The triple SGC combination
is not recommended for further phase 3 evaluation in
patients with advanced urothelial carcinoma.
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the trial: Addenbrooke’s Hospital (DaneshMazhar), Beatson
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Royal Marsden (Robert A. Huddart), Royal Shrewsbury
Hospital (Narayanan Srihari), Southampton General Hospi-
tal (Graham Mead, Simon Crabb), St Barts Hospital (Tom
Powles), St James’s University Hospital (John Chester),
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Appendix B. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
eururo.2014.11.003.
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